We aim to identify CMTM6 as a potential immunotherapeutic target for PAAD based on theoretical implications, and this study is the first to describe CMTM6’s participation within PAAD, both clinically and molecularly. This evidence concerns the gene CMTM6 and pancreatic adenocarcinoma.